01—Abstract
Summary
Summary of the 10-Q filed August 4, 2022. Cited figures are marked; the original filing is the authoritative source.
Ecolab Inc. (ECL) reported its second quarter 2022 financial results, showing a 13% increase in reported net sales year-over-year, reaching $3.58 billiona.
This growth was driven by a combination of pricing actions and volume increases across its segments, with fixed currency sales up 17%. Despite topline growth, reported operating income saw a 5% decrease to $425.8 millionb, and net income attributable to Ecolab declined 1% to $308.3 million. This was primarily due to increased cost of sales, particularly delivered product costs, which more than offset pricing gains.
The company is navigating a challenging macroeconomic environment characterized by inflation and supply chain disruptions, which are impacting its gross margins. The company maintained a strong balance sheet with total assets of $21.2 billionc and total liabilities of $14.0 billion.
Ecolab continues to return capital to shareholders through dividends and share repurchases, demonstrating a commitment to shareholder value. While facing inflationary pressures, Ecolab's diversified business model and strategic pricing initiatives are expected to help mitigate these challenges moving forward.
02—Key points
Key Highlights
- Reported net sales increased 13% to $3.58 billion in Q2 2022 compared to Q2 2021.
- Fixed currency sales grew 17% year-over-year, indicating strong underlying business performance.
- Reported operating income decreased 5% to $425.8 million, impacted by rising cost of sales.
- Net income attributable to Ecolab was $308.3 million, a slight decrease of 1% year-over-year.
- Diluted EPS remained flat at $1.08 for the quarter.
- The company is actively managing its capital structure, with $8.8 billion in total debt and $124.9 million in cash and cash equivalents as of June 30, 2022.
- Ecolab experienced significant growth in its Global Healthcare & Life Sciences segment, with fixed currency sales up 37%, largely due to the Purolite acquisition.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2022, Ecolab Inc. kept $0.09.
- Revenue$3.58B100.0%
- Cost of revenue−$2.21B61.8%
- Gross profit$1.37B38.2%
- Operating costs−$943.7M26.4%
- Operating income$425.8M11.9%
- Interest, other & tax−$117.5M3.3%
- Net income$308.3M8.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2022filed August 4, 2022Financial Statements
Q2 FY2022 against Q2 FY2021
| Line item | Q2 FY2022Q2 FY2021 | Change |
|---|---|---|
| Revenue | $3.58B$3.16B | +13.2% |
| Cost of Revenue | $2.21B$1.84B | +19.9% |
| Gross Profit | $1.37B$1.32B | +3.9% |
| SG&A Expenses | $940.10M$853.30M | +10.2% |
| Operating Income | $425.80M$447.80M | −4.9% |
| Interest Expense | $57.30M$51.70M | +10.8% |
| Net Income | $308.30M$313.60M | −1.7% |
| EPS (Basic) | $1.08$1.09 | −0.9% |
| EPS (Diluted) | $1.08$1.08 | 0.0% |
| Shares Outstanding (Basic) | 285.10M286.00M | −0.3% |
| Shares Outstanding (Diluted) | 286.60M288.80M | −0.8% |
05—Questions
Frequently Asked Questions
What was the primary driver behind the decrease in operating income despite sales growth?
The decrease in operating income was primarily driven by an increase in the cost of sales, specifically delivered product costs, which more than offset the benefits of accelerating pricing and volume increases. This is a common challenge faced by many companies in the current inflationary environment.
How is Ecolab managing the impact of inflation and supply chain issues?
Ecolab is implementing pricing actions to mitigate the impact of higher delivered product costs. They are also focused on operational efficiencies and new business wins across their segments to help offset these inflationary pressures and supply chain disruptions.
What is the outlook for the Global Healthcare & Life Sciences segment?
The Global Healthcare & Life Sciences segment showed strong growth, with fixed currency sales up 37%. This growth was significantly influenced by the Purolite acquisition. Excluding acquisition impacts, sales were flat, with growth in Life Sciences offset by modest declines in Healthcare. The company expects continued pricing and new business growth in Life Sciences to drive future performance.
How is Ecolab returning capital to shareholders?
Ecolab continues to return capital to shareholders through dividend payments and share repurchases. During the first six months of 2022, the company paid $300 million in dividends and repurchased $403 million of its shares.
06—Continue